All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-06-08T11:09:02.000Z

Understanding resistance mechanisms to current standard of care and how to overcome them

By Claire Baker
Featured
Enrique Ocio
Jun 8, 2020
Share:

Bookmark this article

During COMy 2020, Enrique Ocio, Marqués de Valdecilla University Hospital, Santander, ES, spoke to the Multiple Myeloma (MM) Hub about resistance mechanisms to current standard of care and how to overcome them.

Understanding resistance mechanisms to current standard of care and how to overcome them

Although advances in treatment options for MM have improved the outcome of patients in recent years, resistance remains a problem and MM is still considered an incurable disease. Here, Enrique Ocio discusses the importance of understanding the mechanisms behind both primary and secondary resistance in order to overcome them.


More about...
COMyCOMy 2020Immune modulatorsNewly diagnosed multiple myelomaRelapsed/refractory multiple myeloma

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
19 votes - 11 days left ...

Related articles

Add bookmark

NK cell therapy for the treatment of multiple myeloma

At the 2020 Controversies in Multiple Myeloma (COMy) Online Meeting, Michael O’Dwyer, University of Galway, IE, outlined the role of cellular therapies in the treatment of multiple myeloma (MM)....

Jun 22, 2020
Add bookmark

NK cell therapy for the treatment of multiple myeloma

At the 2020 Controversies in Multiple Myeloma (COMy) Online Meeting, Michael O’Dwyer, University of Galway, IE, outlined the role of cellular...

Jun 22, 2020
Add bookmark

Monthly educational Theme | Transplant in Myeloma

This article summarizes transplant in multiple myeloma; including the resources available on the MM Hub.

Nov 6, 2019
Add bookmark

Monthly educational Theme | Transplant in Myeloma

This article summarizes transplant in multiple myeloma; including the resources available on the MM Hub.

Nov 6, 2019

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox